Opinion: 3 lessons from the tobacco settlement on how states should use money from Meta
“Whether it’s nicotine or algorithms, the result is the same: reinforcing a behavior that is harmful to users,” writes Susan Morrisey.
STAT•Susan Morrisey15 SeptSTAT — page 2
70 articlesstatnews.com ↗
Coverage, page 2
page 2 of 4STAT•Susan Morrisey15 Sept
STAT+: Medicare’s AI prior authorization pilot was rushed and full of problems, new documents reveal
The rushed launch of a Medicare pilot to use AI for prior authorization led to delayed care in some instances, new documents reveal.
STAT•Brittany Trang15 Sept
Judge blocks Trump administration plans to limit visa length for grad students, postdocs
A federal judge halted a Trump administration plan to place a four-year cap on the kinds of visas used by graduate students and postdocs
STAT•Jonathan Wosen and Anil Oza14 Sept
Abbott agrees to settlement over closure of largest baby formula plant in the U.S.
Abbott has agreed to a $385 million settlement over the closure of the largest baby formula plant in the U.S., which led to the supply shortages in 2022.
STAT•Associated Press14 Sept
Kennedy to deliver keynote for anti-vaccine group he once led
RFK Jr. worked to distance himself from Children's Health Defense, the anti-vaccine group he once led. Now, he's delivering a keynote at CHD's conference.
STAT•Isabella Cueto14 Sept
STAT+: How $500 explains Republican health policy, and the GLP-1 Rx wave
The one health care policy Republicans agree on, and a look at how rural providers are approaching AI.
STAT•Bob Herman14 Sept
Pennsylvania officials report state’s third death involving measles
A Pennsylvania woman has died from complications associated with measles, the third death in the state this year involving the virus.
STAT•Associated Press14 Sept
STAT+: GSK touts lung cancer data from two drugs
Late-stage results for Definium's LSD treatment, AstraZeneca breast cancer drug fails key trial, and more biotech news from The Readout
STAT•Meghana Keshavan14 Sept
STAT+: Pharmalittle: We’re reading about another AstraZeneca trial failure, a Novo name change, and more
AstraZeneca disclosed that a breast cancer pill failed in a pivotal trial testing it as a first-line therapy in advanced tumors
STAT•Ed Silverman14 Sept
Pennsylvania records third measles-related death amid outbreak
RSV season approaches, a federal judge pauses AAP challenge of RFK J.r vaccine charges, and more health news
STAT•Helen Branswell and Anil Oza14 Sept
STAT+: Definium’s LSD therapy eased anxiety in second large trial
The first wave of biotechs is nearing regulatory approval for psychedelic therapies, a class of treatments that appear to exert rapid benefits.
STAT•Elaine Chen14 Sept
STAT+: What’s in a name? Novo looks to a rebrand
Novo Nordisk is now going by Novo, part of a rebrand that the company hopes can signal a more focused, competitive future.
STAT•Andrew Joseph14 Sept
Opinion: Restoring public trust in science doesn’t have a simple solution. That’s OK
“Messaging can’t substitute for the relational infrastructure needed for building and sustaining trust,” write Michelle Groman and Caroline Montojo.
STAT•Michelle Groman and Caroline Montojo14 Sept
Opinion: Am I a hypocrite for loving football despite CTE?
Sportswriter and football fan Michael Arkush has known about CTE for years. But he increasingly feels uneasy about watching the game he loves.
STAT•Michael Arkush14 Sept
The GOP’s $50 billion rural health fund is coming up short, hospital leaders say
Hospital leaders were excited about the Rural Health Transformation Fund until they saw the fine print.
STAT•Daniel Payne14 Sept
STAT+: Trump’s secretive pharma deals may undermine ‘most-favored nation’ pricing, an analysis suggests
The projected savings from Trump's "most-favored nation" pricing policy might be drastically reduced by secretive deals with pharma companies, a new analysis finds.
STAT•Ed Silverman13 Sept
STAT+: Breast cancer pill from AstraZeneca misses mark in pivotal trial
A pill from AstraZeneca failed to improve outcomes in closely watched breast cancer study, a result that could limit the use of the medicine.
STAT•Andrew Joseph12 Sept
STAT+: Scholar Rock wins FDA approval for first drug to target SMA muscle loss
A late-stage clinical trial found that, when combined with an SMN2-targeting drug, Isembyld caused young patients’ motor skills to improve after a year.
STAT•Jonathan Wosen11 Sept
STAT+: Pharma wins a battle over the cost of wastewater treatment in Europe
An E.U. AG recommended annulling part of a directive that requires drugmakers to finance 80% of the costs of wastewater treatment.
STAT•Ed Silverman11 Sept
U.S. officials declare an end to record-setting cyclospora outbreak, but its origin is still unknown
The largest cyclospora food poisoning outbreak in U.S. history is over, U.S. health officials said, but questions remain over its origin.
STAT•Associated Press11 Sept